Helix BioPharma Corp. (TSE: HBP) recently signed an agreement with BioVectra, a division of Diagnostic Chemicals Limited (BioVectra dcl), for the manufacture of L-DOS47 bulk drug product for human clinical testing.
L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific single domain antibody to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung.
According to John Docherty, Helix's Vice President of Corporate Development:
"The signing of this agreement builds upon previous manufacturing work through which fundamental cGMP processing parameters for L-DOS47 have been developed.
BioVectra dcl is a natural choice for our clinical manufacturing program requirements because in addition to their high calibre capabilities in the cGMP production of biopharmaceuticals, they are also one of the largest North American producers of the urease substance at the heart of our L-DOS47 drug product."Find more details from the press release (a pdf file).
Comment Preview